OMIM References: Difference between revisions

From Embryology
Line 1,082: Line 1,082:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190070 V-KI-RAS2 KIRSTEN RAT SARCOMA 2 VIRAL ONCOGENE HOMOLOG; KRAS2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190070 V-KI-RAS2 KIRSTEN RAT SARCOMA 2 VIRAL ONCOGENE HOMOLOG; KRAS2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602421 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602421 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=219700 CYSTIC FIBROSIS; CF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=219700 CYSTIC FIBROSIS; CF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=124030 CYTOCHROME P450, SUBFAMILY IID; CYP2D]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=124030 CYTOCHROME P450, SUBFAMILY IID; CYP2D]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=108330 CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=108330 CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=151623 LI-FRAUMENI SYNDROME; LFS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=151623 LI-FRAUMENI SYNDROME; LFS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190020 V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG; HRAS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190020 V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG; HRAS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=180200 RETINOBLASTOMA; RB1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=180200 RETINOBLASTOMA; RB1]
Line 1,093: Line 1,093:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=131100 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=131100 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603486 UBIQUITIN-SPECIFIC PROTEASE 4; USP4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603486 UBIQUITIN-SPECIFIC PROTEASE 4; USP4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265120 PULMONARY ALVEOLAR PROTEINOSIS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265120 PULMONARY ALVEOLAR PROTEINOSIS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191325 UBIQUITIN-ACTIVATING ENZYME E1-LIKE; UBE1L]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191325 UBIQUITIN-ACTIVATING ENZYME E1-LIKE; UBE1L]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=102645 ACYLPEPTIDE HYDROLASE; APH]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=102645 ACYLPEPTIDE HYDROLASE; APH]
Line 1,124: Line 1,124:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=156240 MESOTHELIOMA, MALIGNANT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=156240 MESOTHELIOMA, MALIGNANT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601159 CHEMOKINE (C-C) RECEPTOR 1; CMKBR1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601159 CHEMOKINE (C-C) RECEPTOR 1; CMKBR1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=225350 EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL RECESSIVE; EDS4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=225350 EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL RECESSIVE; EDS4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=138350 GLUTATHIONE S-TRANSFERASE, MU 1; GSTM1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=138350 GLUTATHIONE S-TRANSFERASE, MU 1; GSTM1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=136950 PAIRED BASIC AMINO ACID CLEAVING ENZYME; PACE]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=136950 PAIRED BASIC AMINO ACID CLEAVING ENZYME; PACE]
Line 1,154: Line 1,154:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300034 ANGIOTENSIN II RECEPTOR, TYPE 2; AGTR2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300034 ANGIOTENSIN II RECEPTOR, TYPE 2; AGTR2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=172410 PHOSPHOLIPASE A2, GROUP IB; PLA2G1B]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=172410 PHOSPHOLIPASE A2, GROUP IB; PLA2G1B]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=108340 ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=108340 ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602725 INTERFERON-RELATED DEVELOPMENTAL REGULATOR 2; IFRD2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602725 INTERFERON-RELATED DEVELOPMENTAL REGULATOR 2; IFRD2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602913 CYTOKINE-INDUCIBLE KINASE; CNK]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602913 CYTOKINE-INDUCIBLE KINASE; CNK]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300091 FOS-INDUCED GROWTH FACTOR; FIGF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300091 FOS-INDUCED GROWTH FACTOR; FIGF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=118509 CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, BETA POLYPEPTIDE 4; CHRNB4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=118509 CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, BETA POLYPEPTIDE 4; CHRNB4]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114400 CANCER]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114400 CANCER]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601582 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 145-KD; INPP5D]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601582 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 145-KD; INPP5D]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=138981 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR, BETA; CSF2RB]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=138981 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR, BETA; CSF2RB]
Line 1,173: Line 1,173:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602614 TRANSFORMING GROWTH FACTOR-BETA-ACTIVATED KINASE 1; TAK1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602614 TRANSFORMING GROWTH FACTOR-BETA-ACTIVATED KINASE 1; TAK1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=117550 CEREBRAL GIGANTISM]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=117550 CEREBRAL GIGANTISM]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=146510 PALLISTER-HALL SYNDROME; PHS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=146510 PALLISTER-HALL SYNDROME; PHS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602908 B5T OVEREXPRESSED GENE]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602908 B5T OVEREXPRESSED GENE]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=236680 HYDROLETHALUS SYNDROME]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=236680 HYDROLETHALUS SYNDROME]
Line 1,200: Line 1,200:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190230 TRANSFORMING GROWTH FACTOR, BETA-3; TGFB3]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190230 TRANSFORMING GROWTH FACTOR, BETA-3; TGFB3]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=158310 MUCOEPITHELIAL DYSPLASIA, HEREDITARY]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=158310 MUCOEPITHELIAL DYSPLASIA, HEREDITARY]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=183900 SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL TYPE]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=183900 SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL TYPE]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162200 NEUROFIBROMATOSIS, TYPE I; NF1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162200 NEUROFIBROMATOSIS, TYPE I; NF1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162323 TACHYKININ 1 RECEPTOR; TACR1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162323 TACHYKININ 1 RECEPTOR; TACR1]
Line 1,219: Line 1,219:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120150 COLLAGEN, TYPE I, ALPHA-1; COL1A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120150 COLLAGEN, TYPE I, ALPHA-1; COL1A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=118910 CHROMOGRANIN A; CHGA]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=118910 CHROMOGRANIN A; CHGA]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114480 CANCER OF THE BREAST, FAMILIAL; BCS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114480 CANCER OF THE BREAST, FAMILIAL; BCS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=134660 GLUTATHIONE S-TRANSFERASE, PI; GSTP1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=134660 GLUTATHIONE S-TRANSFERASE, PI; GSTP1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114130 CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA; CALCA]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=114130 CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA; CALCA]
Line 1,226: Line 1,226:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109690 BETA-2-ADRENERGIC RECEPTOR; ADRB2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109690 BETA-2-ADRENERGIC RECEPTOR; ADRB2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=172450 PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; PPAT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=172450 PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; PPAT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109400 BASAL CELL NEVUS SYNDROME; BCNS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109400 BASAL CELL NEVUS SYNDROME; BCNS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=173600 PNEUMOTHORAX, SPONTANEOUS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=173600 PNEUMOTHORAX, SPONTANEOUS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=175050 POLYPOSIS, GENERALIZED JUVENILE, WITH PULMONARY ARTERIOVENOUS MALFORMATION]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=175050 POLYPOSIS, GENERALIZED JUVENILE, WITH PULMONARY ARTERIOVENOUS MALFORMATION]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109270 SOLUTE CARRIER FAMILY 4, ANION EXCHANGER, MEMBER 1; SLC4A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109270 SOLUTE CARRIER FAMILY 4, ANION EXCHANGER, MEMBER 1; SLC4A1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=100800 ACHONDROPLASIA; ACH]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=100800 ACHONDROPLASIA; ACH]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=100790 ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG-LIKE 1; ASCL1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=100790 ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG-LIKE 1; ASCL1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=155600 MELANOMA, MALIGNANT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=155600 MELANOMA, MALIGNANT]
Line 1,240: Line 1,240:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601916 ARGININE-RICH PROTEIN]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601916 ARGININE-RICH PROTEIN]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176946 EPHRIN RECEPTOR EphA2; EPHA2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176946 EPHRIN RECEPTOR EphA2; EPHA2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=253300 SPINAL MUSCULAR ATROPHY I; SMA1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=253300 SPINAL MUSCULAR ATROPHY I; SMA1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=253240 MUCUS INSPISSATION OF RESPIRATORY TRACT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=253240 MUCUS INSPISSATION OF RESPIRATORY TRACT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600718 MEMBRANE COMPONENT, CHROMOSOME 4, SURFACE MARKER 1; M4S1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600718 MEMBRANE COMPONENT, CHROMOSOME 4, SURFACE MARKER 1; M4S1]
Line 1,310: Line 1,310:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=150292 LAMININ, GAMMA-2; LAMC2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=150292 LAMININ, GAMMA-2; LAMC2]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190930 TROPOMODULIN; TMOD]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190930 TROPOMODULIN; TMOD]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=220110 COMPLEX IV, MITOCHONDRIAL RESPIRATORY CHAIN, DEFICIENCY OF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=220110 COMPLEX IV, MITOCHONDRIAL RESPIRATORY CHAIN, DEFICIENCY OF]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=150240 LAMININ, BETA-1; LAMB1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=150240 LAMININ, BETA-1; LAMB1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191155 TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 1; TM4SF1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191155 TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 1; TM4SF1]
Line 1,317: Line 1,317:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162341 NEUROMEDIN B RECEPTOR; NMBR]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162341 NEUROMEDIN B RECEPTOR; NMBR]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162643 NEUROPEPTIDE Y RECEPTOR Y3; NPY3R]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=162643 NEUROPEPTIDE Y RECEPTOR Y3; NPY3R]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=187300 TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER; HHT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=187300 TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER; HHT]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=233700 GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL CYTOCHROME-b-POSITIVE FORM I]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=233700 GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL CYTOCHROME-b-POSITIVE FORM I]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=163729 NITRIC OXIDE SYNTHASE 3; NOS3]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=163729 NITRIC OXIDE SYNTHASE 3; NOS3]
Line 1,344: Line 1,344:
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=259450 BRUCK SYNDROME]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=259450 BRUCK SYNDROME]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=151400 LEUKEMIA, CHRONIC LYMPHATIC; CLL]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=151400 LEUKEMIA, CHRONIC LYMPHATIC; CLL]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=145000 HYPERPARATHYROIDISM, FAMILIAL ISOLATED PRIMARY; FIHP]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=145000 HYPERPARATHYROIDISM, FAMILIAL ISOLATED PRIMARY; FIHP]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=264350 PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=264350 PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=144700 RENAL CELL CARCINOMA 1; RCC1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=144700 RENAL CELL CARCINOMA 1; RCC1]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265300 PULMONARY CYSTIC LYMPHANGIECTASIS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265300 PULMONARY CYSTIC LYMPHANGIECTASIS]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265430 PULMONARY HYPOPLASIA]
* [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=265430 PULMONARY HYPOPLASIA]

Revision as of 06:20, 25 March 2010

Introduction

There are many different Online Mendelian Inheritence in Man (OMIM) reference materials used in UNSW Embryology. Selected OMIM references can also be found on the Abnormalities (page 2) of each section of Notes and there are also search buttons that will perform searches using specific term(s) of external databases. Some search results will allow access to the full original document, while others may require a Journal subscription to access the full document.

Students when referencing specific materials should as much as possible cite the original Research article and not Review articles. When wanting to give a broad overview or summaries of the field, the Review articles should be cited (and indicated as "reviews"). Students should also avoid direct text cut and paste and if absolutely necessary should place in "quotation marks" citing the original reference.

About OMIM "Online Mendelian Inheritance in Man OMIM is a comprehensive, authoritative, and timely compendium of human genes and genetic phenotypes. The full-text, referenced overviews in OMIM contain information on all known mendelian disorders and over 12,000 genes. OMIM focuses on the relationship between phenotype and genotype. It is updated daily, and the entries contain copious links to other genetics resources." OMIM


Links: Original Embryo Page | OMIM | Citing OMIM?

Page Links


2010 OMIM Pages by Developmental Topic

Week 1

Fertilization

Spermatozoa Motility

Spermatozoa

Cardiovascular

Tetralogy of Fallot

Atrial Septal Defect

Musculoskeletal

Muscular Dystrophy

Syndactyly


Scoliosis

Congenital Dislocation of the Hip


Head and Neck

Cleft Lip

Cleft Palate

Urogenital

Kidney

Gonad

Gastrointestinal Tract

Hirschsprung Disease


Coelomic Cavity

Diaphragmatic Hernia

Respiratory

187760 THORACOLARYNGOPELVIC DYSPLASIA; TLPD]

1999 OMIM Pages

In 1999 I searched the Online Mendelian Inheritence in Man (OMIM) database and selected a small number of references for each topic. These earlier searches are now slightly out of date, but should still be a good starting point for those interested in the topics.

These pages retain the original earlier site (Version 3) page layout.

Week 1

Fertilization

Week 2

Week 3

Abnormal Development

Neural

Cardiovascular

Musculoskeletal

Gastrointestinal

Head and Neck

Coelomic Cavity

Respiratory

Neural Crest

Senses

Urogenital

Kidney

Gonad

Endocrine